USPTO Examiner DUFFY BRADLEY - Art Unit 1643

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19217172Method of Use for Benzofuran CompoundsMay 2025February 2026Allow811NoNo
19182382METHODS OF TREATING GASTROINTESTINAL INFLAMMATORY DISEASEApril 2025July 2025Allow310NoNo
19006633BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMADecember 2024October 2025Allow1021YesNo
18774123DOSING REGIMEN FOR TREATING INFLAMMATORY BOWEL DISEASEJuly 2024April 2025Allow911YesNo
18753928Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods ThereforJune 2024November 2025Allow1731YesNo
18674755TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIESMay 2024November 2025Allow1831YesNo
18626607CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAMEApril 2024July 2025Abandon1511NoNo
18553326POLYPEPTIDES TARGETING HLA-A*11 AND METHODS OF USE THEREOFSeptember 2023March 2026Allow3000YesNo
18461190OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENESeptember 2023December 2025Abandon2711NoNo
18329562Subcutaneous Formulations Of Anti-CD38 Antibodies And Their UsesJune 2023March 2026Allow3310NoNo
18246173POLYNUCLEOTIDE FOR PHYSIOLOGICAL EXPRESSION IN T-CELLSMarch 2023January 2026Allow3410YesNo
18067948CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAMEDecember 2022January 2024Allow1201NoNo
18001583ANTIBODY THERAPIES FOR SARS-COV-2 INFECTIONDecember 2022March 2026Abandon3910NoNo
17998733SELECTIVE TARGETING OF THE TREML1/MD2 INTERACTION BY SMALL PEPTIDE OR PROTEIN AND ITS USE FOR VACCINE ADJUVANTSNovember 2022February 2026Allow3910NoNo
17917726COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONSOctober 2022February 2026Abandon4001NoNo
17938886CD37-BINDING MOLECULES IMMUNOCONJUGATES THEREOFOctober 2022October 2025Allow3710NoNo
17911937COMBINATION TREATMENT FOR CANCER INVOLVING ANTI-ICOS AND ANTI-PD1 ANTIBODIES, OPTIONALLY FURTHER INVOLVING ANTI-TIM3 ANTIBODIESSeptember 2022January 2026Abandon4101NoNo
17929655COMBINATIONS OF IMMUNOTHERAPIES AND USES THEREOFSeptember 2022March 2025Abandon3130YesNo
17801454METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT ANTIBODYAugust 2022December 2025Abandon4010NoNo
17795500CD28 SINGLE DOMAIN ANTIBODIES AND MULTIVALENT AND MULTISPECIFIC CONSTRUCTS THEREOFJuly 2022September 2025Allow3710NoNo
17813434ANTIBODY CONSTRUCTS FOR FLT3 AND CD3July 2022November 2025Abandon4001NoNo
17793587LIGAND-BINDING FUSION PROTEINSJuly 2022March 2026Allow4411YesNo
17780068POSITIVE ALLOSTERIC MODULATORS OF THE CALCIUM-SENSING RECEPTORMay 2022February 2026Abandon4401NoNo
17745590METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASESMay 2022November 2025Allow4211NoNo
17743727Cysteine Engineered Antibodies and ConjugatesMay 2022October 2025Abandon4110NoNo
17734881PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFSMay 2022August 2025Abandon3910NoNo
17734253MULTISPECIFIC ANTIBODY CONSTRUCTSMay 2022July 2025Allow3811YesNo
17770922NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2April 2022January 2026Allow4511YesNo
17720937MODIFIED ANTIBODY CONSTANT REGIONApril 2022December 2025Allow4411YesNo
17719894FUSION PROTEINS THAT FACILITATE CANCER CELL DESTRUCTIONApril 2022April 2025Allow3601NoNo
17658731GLYCAN-BASED ANTIBODY-DRUG CONJUGATESApril 2022September 2025Allow4121NoNo
17642011DEVICES AND METHODS FOR MODULATING ADMA IN BLOODMarch 2022September 2025Allow4321NoNo
17689388CD19 BINDING AGENTS AND USES THEREOFMarch 2022January 2025Abandon3401NoNo
17682633CELL SURFACE COUPLING OF NANOPARTICLESFebruary 2022May 2025Abandon3810NoNo
17680174Anti-CD30 monoclonal antibodies and chimeric antigen receptorsFebruary 2022August 2023Allow1811YesNo
17670718METHOD FOR CONTROLLING AFFINITY OF ANTIBODY FOR ANTIGEN, ANTIBODY WHOSE AFFINITY FOR ANTIGEN HAS BEEN ALTERED, AND ITS PRODUCTION METHODFebruary 2022February 2025Allow3601NoNo
17666018Humanized anti-DKK2 antibody and uses thereofFebruary 2022December 2024Abandon3501NoNo
17633046MODIFIED HUMAN VARIABLE DOMAINSFebruary 2022October 2025Abandon4501NoNo
17586455MULTISPECIFIC ANTIBODIESJanuary 2022July 2025Abandon4111NoNo
17645737VACCINEDecember 2021March 2022Allow300YesNo
17645741VACCINEDecember 2021November 2022Allow1120YesNo
17542948Anti-TfR1 Antibody MAb11-22.1 Conjugates for Cancer TreatmentDecember 2021January 2024Allow2611YesNo
17530211GENETICALLY MODIFIED NK-92 CELLS HAVING A SAFETY SWITCHNovember 2021April 2025Allow4021NoNo
17525512HUMAN MONOCLONAL ANTIBODY HUMAN CD134 (OX40) AND METHODS OF MAKING AND USING SAMENovember 2021February 2025Allow3910NoNo
17522663IN VIVO TARGETING OF CELLS WITH LIGAND-CONJUGATED PARTICLESNovember 2021February 2026Abandon5121NoNo
17518123CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOFNovember 2021November 2024Allow3710NoNo
17515250PD-1-CD28 FUSION PROTEINS AND THEIR USE IN MEDICINEOctober 2021November 2025Allow4921NoNo
17488698METHOD FOR GENERATING AVID-BINDING MULTISPECIFIC ANTIBODIESSeptember 2021July 2025Allow4510YesNo
17479930Combination Therapy for the Treatment of CancerSeptember 2021January 2026Abandon5221NoNo
17433155Novel Fusion Proteins Specific for CD137 and GPC3August 2021July 2025Allow4721YesNo
17405104ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) IMMUNOADHESIN MICROBODYAugust 2021February 2024Allow3001YesNo
17431664Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding PartnerAugust 2021May 2025Abandon4511NoNo
17383765Anti-Abeta AntibodiesJuly 2021June 2025Allow4631YesNo
17305577FUSION CONSTRUCTS AND METHODS OF USING THEREOFJuly 2021August 2024Allow3821YesNo
17351724Combination Therapy for the Treatment of CancerJune 2021May 2025Abandon4721NoNo
17342518T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use ThereofJune 2021August 2025Abandon5011NoNo
17328118CD70 Binding Molecules and Methods of Use ThereofMay 2021August 2024Allow3911NoNo
17318590CELL SURFACE COUPLING OF NANOPARTICLESMay 2021October 2021Allow500NoNo
17317824AFFINITY ENTITIES COMPRISING A TCR-LIKE ANTIBODY BINDING DOMAIN WITH HIGH AFFINITY AND FINE SPECIFICITY AND USES OF SAMEMay 2021November 2024Allow4201YesNo
17307158COMPOSITIONS AND METHODS FOR TREATING CANCERMay 2021May 2025Abandon4811NoNo
17235805IMMUNOGLOBULIN VARIANTS AND USES THEREOFApril 2021August 2024Abandon4010NoNo
17285836PRODUCTIVITY-ENHANCED ANTIBODY AND METHOD FOR PRODUCING SAMEApril 2021November 2025Allow5531YesNo
17227536Tetravalent Antibody-Drug Conjugates and Use ThereofApril 2021December 2023Allow3200YesNo
17217839GENETICALLY MODIFIED NK-92 CELLS AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF CANCERMarch 2021August 2021Allow510NoNo
17279775METHODS OF SELECTING TREATMENT FOR CXCR4-ASSOCIATED CANCERMarch 2021August 2025Abandon5311NoNo
17210124Antibodies Targeted to Fungal Cell Wall PolysaccharidesMarch 2021November 2024Abandon4401NoNo
17278075METHODS OF REVERSING TICAGRELOR ACTIVITYMarch 2021November 2025Allow5631YesNo
17200322EGFR-DIRECTED CAR THERAPY FOR GLIOBLASTOMAMarch 2021August 2024Abandon4101NoNo
17200287MATERIALS AND METHODS FOR MODULATING DELTA CHAIN MEDIATED IMMUNITYMarch 2021January 2026Abandon5841NoNo
17198179ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOFMarch 2021June 2024Allow3911NoNo
17176858METHOD FOR ENGINEERING IMMUNOGLOBULINSFebruary 2021June 2024Abandon4010NoNo
17268174CANCER STEM CELL MARKER AND CANCER STEM CELL TARGETING DRUGFebruary 2021April 2025Abandon5111NoNo
17172694BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOFFebruary 2021May 2022Allow1521YesNo
17172698BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOFFebruary 2021October 2025Allow5731NoYes
17172700BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOFFebruary 2021January 2025Allow4811NoNo
17168100CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOFFebruary 2021October 2021Allow811YesNo
17264735MULTISPECIFIC TREG BINDING MOLECULESJanuary 2021October 2024Abandon4501NoNo
17151911BIOLOGICAL PRODUCTSJanuary 2021December 2023Abandon3410NoNo
17150272B CELL MATURATION ANTIGEN BINDING PROTEINSJanuary 2021January 2024Allow3611NoNo
17150626PRO-ANTIBODY THAT REDUCES OFF-TARGET TOXICITYJanuary 2021November 2025Allow5831YesNo
17148337MULTISPECIFIC TREG BINDING MOLECULESJanuary 2021April 2023Abandon2701NoNo
17121622Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating MethodsDecember 2020November 2024Abandon4711NoNo
16972319COMPLEMENT C4D ASSAYDecember 2020February 2026Abandon6031NoNo
17112206METHODS FOR PREVENTING ACUTE KIDNEY INJURYDecember 2020September 2025Allow5721YesNo
17104983CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFNovember 2020July 2024Allow4422YesNo
17103190USE OF HEXOKINASE-2 IN DETECTION OF RARE TUMOR CELLS IN BODY FLUID SAMPLE AND KITNovember 2020October 2021Allow1021NoNo
17096513METHODS OF ASSESSING AND TREATING CANCER IN SUBJECTS HAVING DYSREGULATED LYMPHATIC SYSTEMSNovember 2020July 2025Allow5631YesNo
17051731METHODS AND SYSTEMS FOR SELECTION AND TREATMENT OF PATIENTS WITH INFLAMMATORY DISEASESOctober 2020November 2024Allow4811YesNo
17084156THERAPEUTIC CD47 ANTIBODIESOctober 2020October 2023Abandon3601NoNo
17078903TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOROctober 2020January 2024Allow3821YesNo
17048739Switch Molecule And Switchable Chimeric Antigen ReceptorOctober 2020January 2024Allow3941YesNo
17032482DISRUPTION OF THE WAVE3 PROTEIN COMPLEX FOR SUPPRESSION OF INVASION AND METASTASISSeptember 2020May 2023Allow3201YesNo
17040426COMBINATION OF NEAR INFRARED PHOTOIMMUNOTHERAPY TARGETING CANCER CELLS AND HOST-IMMUNE ACTIVATIONSeptember 2020January 2025Abandon5231NoNo
16982723FC VARIANT COMPOSITIONS AND METHODS OF USE THEREOFSeptember 2020February 2024Abandon4131YesNo
17025980PRODUCTION OF HETEROMULTIMERIC PROTEINSSeptember 2020June 2023Abandon3210NoNo
17023835Modified Cell with Enhanced Functionality and Cellular Therapy thereofSeptember 2020July 2023Allow3411YesNo
17021423Anti-MET Antibodies and Methods of Use ThereofSeptember 2020September 2023Allow3611NoNo
16980730MULTIFUNCTIONAL MOLECULES THAT BIND TO CALRETICULIN AND USES THEREOFSeptember 2020June 2024Allow4511YesNo
16980816BISPECIFIC ANTIBODY CAR CELL IMMUNOTHERAPYSeptember 2020May 2024Abandon4401NoNo
16994795ANTI-MICA ANTIGEN BINDING FRAGMENTS, FUSION MOLECULES, CELLS WHICH EXPRESS AND METHODS OF USINGAugust 2020August 2023Allow3611NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DUFFY, BRADLEY.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
4
(57.1%)
Examiner Reversed
3
(42.9%)
Reversal Percentile
65.0%
Higher than average

What This Means

With a 42.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
78
Allowed After Appeal Filing
19
(24.4%)
Not Allowed After Appeal Filing
59
(75.6%)
Filing Benefit Percentile
33.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 24.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DUFFY, BRADLEY - Prosecution Strategy Guide

Executive Summary

Examiner DUFFY, BRADLEY works in Art Unit 1643 and has examined 944 patent applications in our dataset. With an allowance rate of 51.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner DUFFY, BRADLEY's allowance rate of 51.9% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DUFFY, BRADLEY receive 1.82 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DUFFY, BRADLEY is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +54.2% benefit to allowance rate for applications examined by DUFFY, BRADLEY. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.7% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 35.6% of cases where such amendments are filed. This entry rate is in the 53% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 84.4% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 65.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 59.5% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.2% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.3% of allowed cases (in the 75% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.